Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,000 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $1.11 during trading hours on Wednesday, reaching $68.25. 4,313,963 shares of the stock traded hands, compared to its average volume of 4,214,635. The company has a 50 day moving average price of $73.78 and a 200 day moving average price of $83.83. The firm has a market capitalization of $41.11 billion, a price-to-earnings ratio of 28.94, a P/E/G ratio of 2.79 and a beta of 1.13. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.66 EPS. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on EW shares. The Goldman Sachs Group lowered their price objective on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research report on Friday, July 26th. UBS Group lowered their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday. Citigroup lifted their price target on Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. Truist Financial lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $110.00 to $82.00 in a research report on Thursday, July 25th. Finally, Oppenheimer lowered their price target on Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating for the company in a research report on Thursday, July 25th. Fifteen investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $80.81.

Institutional Investors Weigh In On Edwards Lifesciences

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after acquiring an additional 600,994 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after acquiring an additional 809,605 shares during the period. Brown Advisory Inc. grew its stake in shares of Edwards Lifesciences by 20.1% during the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after acquiring an additional 3,048,274 shares during the period. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after acquiring an additional 393,109 shares during the period. Finally, Norges Bank bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $648,540,000. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.